Home » Stocks » IBRX

ImmunityBio, Inc. (IBRX)

Stock Price: $17.38 USD 0.12 (0.70%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $17.35 -0.03 (-0.17%) Apr 16, 7:55 PM
Market Cap 6.66B
Revenue (ttm) 111,000
Net Income (ttm) -92.38M
Shares Out 103.55M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $17.38
Previous Close $17.26
Change ($) 0.12
Change (%) 0.70%
Day's Open 16.41
Day's Range 16.15 - 17.38
Day's Volume 896,410
52-Week Range 3.16 - 45.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.

1 week ago - Zacks Investment Research

ImmunityBio Inc (NASDAQ: IBRX) has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants. Just 14-16 days after the single dose of the vacci...

1 week ago - Benzinga

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today reported initial data indicating that a single subcutaneous injection of the company...

1 week ago - Business Wire

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M...

2 weeks ago - Business Wire

ImmunityBio Inc (NASDAQ: IBRX) has announced the publication of Phase 1 study data of its Ad5 PSA/MUC-1/ brachyury-based immunotherapy vaccine for metastatic castration-resistant prostate cancer. Journa...

2 weeks ago - Benzinga

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the publication of Phase I data in The Journal of ImmunoTherapy of Cancer ...

2 weeks ago - Business Wire

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the publication of preclinical data in the Journal for ImmunoTherapy of Ca...

3 weeks ago - Business Wire

ImmunityBio Inc (NASDAQ: IBRX) says it will make its first COVID-19 vaccine in South Africa by The Biovac Institute, a partly state-owned company, once regulators approve it, reports Bloomberg. Producti...

4 weeks ago - Benzinga

NantKwest's Soon-Shiong on BioTech and the Future of Newspapers

YouTube video

Mar.12 -- NantKwest Chairman Dr. Patrick Soon-Shiong discusses the completion of the reverse merger with ImmunityBio and the future of the Los Angeles Times. Soon-Shiong speaks exclusively with Bloomber...

Other stocks mentioned: NK
1 month ago - Bloomberg Markets and Finance

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. T...

Other stocks mentioned: NK
1 month ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote e...

Other stocks mentioned: NK
1 month ago - Business Wire

CULVER CITY & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics c...

Other stocks mentioned: NK
1 month ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institu...

Other stocks mentioned: NK
1 month ago - Business Wire

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley ...

Other stocks mentioned: NK
1 month ago - Business Wire

The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's (NASDAQ: NK) merger partner, ImmunityBio Inc, to include sublingual boosts (cohort C...

Other stocks mentioned: NK
2 months ago - Benzinga

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today...

Other stocks mentioned: NK
2 months ago - Business Wire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of NantKwest, Inc. ...

Other stocks mentioned: NK
2 months ago - Business Wire

BERWYN, Pa., Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning possibl...

Other stocks mentioned: NK
2 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty against cell...

Other stocks mentioned: NK
2 months ago - Business Wire

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.

Other stocks mentioned: NK
2 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...

Other stocks mentioned: NK
3 months ago - Business Wire

Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: Nantkwest ...

Other stocks mentioned: NK
3 months ago - Benzinga

EL SEGUNDO & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immunotherapy c...

Other stocks mentioned: NK
3 months ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman...

Other stocks mentioned: NK
3 months ago - Business Wire

"Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.

Other stocks mentioned: NK
3 months ago - The Motley Fool

PHILADELPHIA, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.

Other stocks mentioned: NK
3 months ago - GlobeNewsWire

WILMINGTON, Del., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach...

Other stocks mentioned: NK
3 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest shareholders. Unde...

Other stocks mentioned: NK
3 months ago - Business Wire

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York Cit...

Other stocks mentioned: NK
3 months ago - PRNewsWire

WILMINGTON, Del., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ GS: NK) regarding possible breaches of fiduciary dutie...

Other stocks mentioned: NK
3 months ago - GlobeNewsWire

NantKwest's Patrick Soon-Shiong on reverse merger with ImmunityBio

YouTube video

NantKwest announces a reverse merger with a frequent collaborator ImmunityBio in a stock-for-stock deal. Patrick Soon-Shiong, NantKwest executive chairman and NantWorks chairman and CEO, joins CNBC's "S...

Other stocks mentioned: NK
3 months ago - CNBC Television

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, DNLI, MCRB, NK, RCKT
3 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

Other stocks mentioned: NK
3 months ago - Business Wire

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. ("NantKwest" or the "Co...

Other stocks mentioned: NK
3 months ago - PRNewsWire

A merger agreement with a fellow immunotherapy company is exciting investors today.

Other stocks mentioned: NK
3 months ago - The Motley Fool

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics...

Other stocks mentioned: NK
3 months ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sa...

Other stocks mentioned: NK
4 months ago - Business Wire

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics...

Other stocks mentioned: NK
5 months ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven operational s...

Other stocks mentioned: NK
5 months ago - Business Wire

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics...

Other stocks mentioned: NK
5 months ago - Business Wire

EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy...

Other stocks mentioned: NK
6 months ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, wil...

Other stocks mentioned: NK
6 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Brink Biologics, Inc. (“Brink”), a NantKwest, Inc.

Other stocks mentioned: NK
7 months ago - Business Wire

EL SEGUNDO, Calif. & CULVER CITY, Calif.

Other stocks mentioned: NK
7 months ago - Business Wire

LOS ANGELES, and EL SEGUNDO, Calif., Aug. 10, 2020 /PRNewswire/ -- CBR® by Generate Life Sciences, the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natur...

Other stocks mentioned: NK
8 months ago - PRNewsWire

NantKwest (NK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: NK
8 months ago - Zacks Investment Research

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten ...

Other stocks mentioned: NK
9 months ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an ...

Other stocks mentioned: NK
9 months ago - Business Wire

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market ...

Other stocks mentioned: NK
9 months ago - Business Wire

Investors are excited about the biotech's COVID-19 vaccine targeting a different part of the novel coronavirus.

Other stocks mentioned: NK
9 months ago - The Motley Fool

About IBRX

ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its n... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Patrick Soon-Shiong
Employees
265
Stock Exchange
NASDAQ
Ticker Symbol
IBRX
Full Company Profile

Financial Performance

In 2020, ImmunityBio's revenue was $111,000, an increase of 158.14% compared to the previous year's $43,000. Losses were -$92.38 million, 40.4% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ImmunityBio is 25.00, which is an increase of 43.84% from the latest price.

Price Target
$25.00
(43.84% upside)